Biomimetic vesicles for the selective delivery of cisplatin for glioblastoma treatment

Glioblastoma (GBM, IDH-wildty pe) is the deadliest brain tumor accounting for approximately 50% of malignant CNS tumors, and more effective therapies are urgently needed. Cisplatin (CisPt) is a potent alkylating agent used to treat different types of cancer. CisPt proved cytotoxic activity also against glioblastoma in vitro, but its efficacy in vivo is limited by the poor blood-brain barrier (BBB) permeability. This limitation, along with the systemic toxicity associated with the administration of CisPt, stimulates the development of different nanosystems for the selective delivery of this drug. Recently, our research group developed human GBM cell membrane-derived vesicles (CMVs), retaining the complexity and homing ability of cell membranes, while overcoming the limits of naturally secreted extracellular vesicles. Following, the CMVs BBB crossing ability was assessed in vitro; then, CMVs were loaded with CisPt by following two different drug loading procedures, and the cytotoxicity of CisPt-loaded CMVs was verified on GBM cells.